163 related articles for article (PubMed ID: 33205005)
1. Transgenic goats producing an improved version of cetuximab in milk.
Laible G; Cole S; Brophy B; Maclean P; How Chen L; Pollock DP; Cavacini L; Fournier N; De Romeuf C; Masiello NC; Gavin WG; Wells DN; Meade HM
FASEB Bioadv; 2020 Nov; 2(11):638-652. PubMed ID: 33205005
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab produced from a goat mammary gland expression system is equally efficacious as innovator cetuximab in animal cancer models.
Wang Q; Gavin W; Masiello N; Tran KB; Laible G; Shepherd PR
Biotechnol Rep (Amst); 2020 Dec; 28():e00533. PubMed ID: 33024714
[TBL] [Abstract][Full Text] [Related]
3. Why is there no biosimilar of Erbitux®?
Douez E; D'Atri V; Guillarme D; Antier D; Guerriaud M; Beck A; Watier H; Foucault-Fruchard L
J Pharm Biomed Anal; 2023 Sep; 234():115544. PubMed ID: 37418870
[TBL] [Abstract][Full Text] [Related]
4. Function characterization of a glyco-engineered anti-EGFR monoclonal antibody cetuximab in vitro.
Yi CH; Ruan CP; Wang H; Xu XY; Zhao YP; Fang M; Ji J; Gu X; Gao CF
Acta Pharmacol Sin; 2014 Nov; 35(11):1439-46. PubMed ID: 25263334
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E
J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119
[TBL] [Abstract][Full Text] [Related]
6. [Relationship between the insulin-like growth factor 1 receptor signaling pathway and the resistance of nasopharyngeal carcinoma to cetuximab].
Zuo Q; Luo RC
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):575-9. PubMed ID: 21122407
[TBL] [Abstract][Full Text] [Related]
7. Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody.
Huang ZQ; Buchsbaum DJ; Raisch KP; Bonner JA; Bland KI; Vickers SM
J Surg Res; 2003 May; 111(2):274-83. PubMed ID: 12850474
[TBL] [Abstract][Full Text] [Related]
8. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab.
Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS
J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124
[TBL] [Abstract][Full Text] [Related]
9. Bacterial production and structure-functional validation of a recombinant antigen-binding fragment (Fab) of an anti-cancer therapeutic antibody targeting epidermal growth factor receptor.
Kim JH; Sim DW; Park D; Jung TG; Lee S; Oh T; Ha JR; Seok SH; Seo MD; Kang HC; Kim YP; Won HS
Appl Microbiol Biotechnol; 2016 Dec; 100(24):10521-10529. PubMed ID: 27470143
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
11. Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.
Veluchamy JP; Spanholtz J; Tordoir M; Thijssen VL; Heideman DA; Verheul HM; de Gruijl TD; van der Vliet HJ
PLoS One; 2016; 11(6):e0157830. PubMed ID: 27314237
[TBL] [Abstract][Full Text] [Related]
12. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells.
Arnoletti JP; Buchsbaum DJ; Huang ZQ; Hawkins AE; Khazaeli MB; Kraus MH; Vickers SM
J Gastrointest Surg; 2004 Dec; 8(8):960-9; discussion 969-70. PubMed ID: 15585383
[TBL] [Abstract][Full Text] [Related]
14. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.
Yoshida T; Okamoto I; Okabe T; Iwasa T; Satoh T; Nishio K; Fukuoka M; Nakagawa K
Int J Cancer; 2008 Apr; 122(7):1530-8. PubMed ID: 18033688
[TBL] [Abstract][Full Text] [Related]
15. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
Fujii R; Schlom J; Hodge JW
J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
[TBL] [Abstract][Full Text] [Related]
16. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.
Yoon J; Koo KH; Choi KY
Cancer Res; 2011 Jan; 71(2):445-53. PubMed ID: 21118963
[TBL] [Abstract][Full Text] [Related]
17. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab: from bench to bedside.
Vincenzi B; Zoccoli A; Pantano F; Venditti O; Galluzzo S
Curr Cancer Drug Targets; 2010 Feb; 10(1):80-95. PubMed ID: 20088790
[TBL] [Abstract][Full Text] [Related]
19. IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR.
Roberti MP; Barrio MM; Bravo AI; Rocca YS; Arriaga JM; Bianchini M; Mordoh J; Levy EM
Breast Cancer Res Treat; 2011 Nov; 130(2):465-75. PubMed ID: 21308409
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]